Predictive value of vascular endothelial growth factor polymorphisms for maintenance bevacizumab efficacy in metastatic colorectal cancer: an ancillary study of the PRODIGE 9 phase III trial.

Date publication

décembre 2022

Journal

Therapeutic advances in medical oncology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr BOUCHE Olivier , Pr GHIRINGHELLI François

Tous les auteurs :
de Rauglaudre B, Sibertin-Blanc C, Fabre A, Le Malicot K, Bennouna J, Ghiringhelli F, Taïeb J, Boige V, Bouché O, Chatellier T, Faroux R, François E, Jacquot S, Genet D, Mulot C, Olschwang S, Seitz JF, Aparicio T, Dahan L

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/36601631

Résumé

Several studies have reported the impact of single nucleotide polymorphisms (SNPs) in vascular endothelial growth factor () pathway genes on the efficacy of bevacizumab in metastatic colorectal cancer (mCRC), but results are still inconsistent. The PRODIGE 9 phase III study compared bevacizumab maintenance observation alone after induction chemotherapy with FOLFIRI plus bevacizumab.

Mots clés

VEGF, angiogenesis, metastatic colorectal cancer, prognostic biomarker, single nucleotide polymorphism

Référence

Ther Adv Med Oncol. 2022 12 26;14:17588359221141307